Commonwealth Equity Services LLC Buys 1,151 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Commonwealth Equity Services LLC grew its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 22.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,357 shares of the biotechnology company’s stock after buying an additional 1,151 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Sarepta Therapeutics were worth $773,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in SRPT. Wellington Management Group LLP boosted its stake in Sarepta Therapeutics by 32.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after purchasing an additional 665,087 shares during the period. Soros Fund Management LLC acquired a new position in shares of Sarepta Therapeutics during the third quarter worth about $25,800,000. Swedbank AB bought a new position in shares of Sarepta Therapeutics during the fourth quarter worth about $16,706,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Sarepta Therapeutics by 16,717.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company’s stock worth $10,602,000 after buying an additional 84,926 shares in the last quarter. Finally, Erste Asset Management GmbH raised its position in Sarepta Therapeutics by 11.3% in the 4th quarter. Erste Asset Management GmbH now owns 708,248 shares of the biotechnology company’s stock valued at $86,116,000 after buying an additional 72,183 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on SRPT. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $163.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Royal Bank of Canada lowered shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their price target for the company from $161.00 to $87.00 in a research note on Monday. Needham & Company LLC reissued a “buy” rating and set a $202.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Scotiabank decreased their price objective on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a report on Thursday, March 20th. Finally, HC Wainwright upgraded Sarepta Therapeutics from a “sell” rating to a “neutral” rating and set a $75.00 target price on the stock in a report on Wednesday. Six analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $164.05.

Sarepta Therapeutics Stock Up 0.9 %

SRPT opened at $62.47 on Thursday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The stock has a fifty day moving average of $99.40 and a 200-day moving average of $114.66. Sarepta Therapeutics, Inc. has a fifty-two week low of $60.70 and a fifty-two week high of $173.25. The company has a market capitalization of $6.06 billion, a P/E ratio of 49.98 and a beta of 0.79.

Insiders Place Their Bets

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now directly owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.